ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR150/036/ERR15009136/ERR15009136.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR150/035/ERR15009135/ERR15009135.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR150/033/ERR15009133/ERR15009133.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR150/034/ERR15009134/ERR15009134.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR150/037/ERR15009137/ERR15009137.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR150/038/ERR15009138/ERR15009138.fastq.gzprimary200OKGenomicsUKT_womenshealthUniversity Womens Hospitalhttps://www.ebi.ac.uk/ena/browser/view/PRJEB88920xref:EuropePMC:PMC12285141SGK1 plasmids were commercially purchased from MRC PPU Dundee, UK and have been previously characterised for their function. SGK1 and its variants were subcloned into the pVAX.A120 vector containing, a poly(A)-120 tail using sticky-end ligation. The clones were then subject to sanger sequencing to confirm the assmembly and their mutational status.ENAfalseOptimizing the use of in vitro Transcribed SGK1-mRNA as a therapeutic tool to treat female infertilityIvtmRNA and SGK12025-04-302025-04-30PRJEB88920